Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the ...

After raising $42 million in a series C1 round, Lanova Medicines Ltd. is advancing its lead phase III antibody-drug conjugate ...

( MENAFN - GlobeNewsWire - Nasdaq) Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus' broadly targeted, short duration systemic immune ...

Indaptus Therapeutics (INDP) announced a clinical supply agreement with BeiGene (BGNE). Building on Indaptus’ preclinical observation ...

Promising results from the anti–LAG-3/anti–PD-1 combo for melanoma, FDA approval of inavolisib for PIK3CA-mutant breast cancer, significant survival benefits from talazoparib and enzalutamide in ...

Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

Opdivo showed a 52% progression-free survival advantage over Adcetris in newly diagnosed Hodgkin’s lymphoma, according to a ...

Astellas Pharma Ltd. today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in ...

A partial clinical hold was placed on the registrational trial after results showed variance between squamous and ...